# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Tarsus Pharmaceuticals announced the pricing of an underwritten public offering of 2,812,500 shares of its common stock at a pu...
Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its co...
Goldman Sachs analyst Andrea Tan maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral and raises the price target f...
HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price t...
Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Oppenheimer analyst Francois Brisebois reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the pric...